Trump's surgeon general pick sells supplement with ingredient banned by the Pentagon

A dietary supplement promoted by radiologist Dr Nicole Saphier — the US president's nominee for surgeon general — as a brand partner has been found to contain an ingredient that the US Department of Defense (the Pentagon) bans for military personnel, according to a Guardian review. The product is marketed as a 'wellness' supplement and contains a substance the Pentagon removed from its Active Military Ingredient list on safety grounds in 2023.

The surgeon general is the title of the official who heads the US Public Health Service Commissioned Corps and provides official federal-level public-health advice. The role carries scientific authority across a wide range — from anti-smoking campaigns to nutrition guidance, from epidemic preparedness to children's screen-time warnings. Saphier's nomination is in the approval process at the Senate Health Committee; the Guardian's findings have sparked a debate expected to surface at the confirmation hearings.

The Guardian confirmed the overlap by comparing the product's ingredient list with the Pentagon's banned-ingredient catalogue. The Pentagon bans certain supplement ingredients — particularly those with stimulant effects — on grounds of military personnel performance and health safety; the list is regularly updated and managed by the Operation Supplement Safety (OPSS) programme. An OPSS spokesperson told the Guardian: 'ingredients on the list are banned because they are not deemed suitable for military use; however, this does not mean the ingredient is banned by the FDA for civilian use' — an important distinction highlighting the gap between the two regulatory frameworks.

Dietary supplements in the US are subject to a different regulatory framework from drugs at the FDA. Under the 1994 Dietary Supplement Health and Education Act (DSHEA), supplements do not require FDA approval before reaching the market; the manufacturer is responsible for safety and label accuracy, and the FDA can act only after a product is on the market. According to an analysis by Guardian health-policy reporter Jessica Glenza, this framework has accelerated the supplement industry's growth but created regulatory gaps — particularly when public figures' brand partnerships are involved.

Regulatory experts say a surgeon general nominee's connection to a commercial supplement brand could be problematic from a conflict-of-interest standpoint. Professor Leana Wen of George Washington University's School of Public Health told the Guardian that 'the public's perception of the surgeon general's health advice as independent of commercial interests is critical to the role's foundation of public trust.' Wen, a former Baltimore health commissioner, added that 'any financial tie a person in this position has to any commercial health product must be fully resolved before confirmation.'

A representative for Dr Saphier told the Guardian: 'Dr Saphier conducted all evaluations regarding the product's scientific formulation with independent experts; the product complies with all FDA requirements and is legal for civilian use.' The representative also said that, if confirmed, Saphier would 'resolve all commercial ties in line with federal ethics rules.' The point that the Pentagon ban is independent of civilian FDA regulation is central to Saphier's defence.

The supplement industry in the US is a market exceeding 60 billion dollars annually; the sector has grown rapidly over the past decade, with social-media influencers and public figures' brand partnerships a significant driver of that growth. The Guardian emphasised that the sector's marketing practices are ahead of the regulatory framework — particularly in the 'wellness' and 'longevity' categories, where the scientific-evidence standard is weak. Industry bodies such as the Council for Responsible Nutrition (CRN) argue the current framework is adequate.

The Senate Health Committee's approval process will continue in the coming weeks. Committee member Democratic Senator Patty Murray (Washington), in a statement following the Guardian's findings, said that 'for a position requiring scientific authority like surgeon general, the nominee's relationship with commercial health products must be examined transparently.' Republican committee members, for their part, emphasise Saphier's expertise in radiology and her experience in public-health communication.

The conflict-of-interest issue is a recurring debate in the appointment of US public-health officials. Previous surgeons general have also been scrutinised over various commercial ties, and most resolved their financial connections before confirmation. The Guardian noted that the Saphier case has reheated the broader debate in the US over the regulation of the supplement industry and the conflict-of-interest standards for public-health officials.

This article is not medical advice. The use of dietary supplements, especially when taken together with prescription medication, should be assessed in consultation with a health professional. The Guardian announced it will publish a follow-up report on how Saphier's Senate confirmation hearings progress in the coming weeks and on any potential reform debates over the supplement industry's regulatory framework.